FDA gives final approval to Teva for generic Actonel

JERUSALEM The Food and Drug Administration has given Teva final approval for its generic version of the Proctor & Gamble osteoporosis drug Actonel, according to Globes online.

The two companies are in litigation over the drug, which was heard in November 2006 by the U.S. District Court for the District of Delaware. The judgment has not yet been handed down.

As part of the pending litigation, Teva has to inform Proctor & Gamble within 30 days of any launch activities, but the Israeli company has not yet done so.